PFIZER REPORTS SECOND-QUARTER 2016 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Pfizer (PFE) Tops Q2 EPS by 2c
August 2, 2016 6:46 AM EDTPfizer (NYSE: PFE) reported Q2 EPS of $0.64, $0.02 better than the analyst estimate of $0.62. Revenue for the quarter came in at $13.1 billion versus the consensus estimate of $13.01 billion.
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our continued sharp focus on executing against the distinct strategies for both our Innovative Health and Essential Health businesses has delivered a strong financial performance during the second quarter as well as for... More
